Teva starts phase 1 trial

According to Teva started a phase 1 trial of its ALK inhibitor, CEP-37440, as of August 2013. The trial # is NCT01922752. They currently list 4 test sites, one of which is recruiting.

See the following link for details:

This entry was posted in Brain metastases, CEP-37440, Lung cancer, Potential Treatments, Research. Bookmark the permalink.

Leave a Reply